A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643].
BACKGROUND
Decision aids are often advocated as a means to assist patient and health care provider decision making when faced with complicated treatment or screening decisions. Despite an exponential growth in the availability of decision aids in recent years, their impact on long-term treatment decisions and patient adherence is uncertain due to a paucity of rigorous studies. The choice of antithrombotic therapy for nonvalvular atrial fibrillation (NVAF) is one condition for which a trade-off exists between the potential risks and benefits of competing therapies, and the need to involve patients in decision making has been clearly identified. This study will evaluate whether an evidence-based patient decision aid for patients with NVAF can improve the appropriateness of antithrombotic therapy use by patients and their family physicians.


METHODS
A multi-center, two-armed cluster randomized trial based in community family practices in which patients with NVAF will be randomized to decision aid or usual care. Patients will receive one of four decision aids depending on their baseline stroke risk. The primary outcome is the provision of "appropriate antithrombotic therapy" at 3 months to study participants (appropriateness defined as per the 2001 American College of Chest Physicians recommendations for NVAF). In addition, the impact of this decision aid on patient knowledge, decisional conflict, well-being, and adherence will be assessed after 3 months, 6 months, and 12 months.
McAlister
Finlay A
FA
The Division of General Internal Medicine, University of Alberta, Edmonton, Canada. Finlay.McAlister@ualberta.ca
Man-Son-Hing
Malcolm
M
Straus
Sharon E
SE
Ghali
William A
WA
Gibson
Paul
P
Anderson
David
D
Cox
Jafna
J
Fradette
Miriam
M
D001281:Atrial Fibrillation / Q000150:complications*; D002985:Clinical Protocols; D003661:Decision Support Techniques; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D018579:Patient Selection; D018401:Sample Size; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*
D005343:Fibrinolytic Agents